

## Solomon Islands Support for Measles-Rubella Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Solomon Islands				
<b>2. Grant number:</b> 1820-SLB-18e-X / 18-SLB-08k-Y				
<b>3. Date of Decision Letter:</b> December 21, 2017				
<b>4. Date of the Partnership Framework Agreement:</b> April 29, 2013				
<b>5. Programme title:</b> New Vaccine Support (NVS), Measles-Rubella first and second dose routine (two dose schedule) Routine				
<b>6. Vaccine type:</b> Measles-Rubella				
<b>7. Requested product presentation and formulation of vaccine:</b> Measles Rubella, 10 dose(s) per vial, LYOPHILISED				
<b>8. Programme duration<sup>1</sup>:</b> 2018 - 2020				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement)				
	2018	2019	2020	Total <sup>2</sup>
Programme Budget (US\$)	25,000	18,000	14,000	57,000
<b>10. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>3</sup>				
<b>Type of supplies to be purchased with Gavi funds in each year (Routine)</b>		<b>2018</b>		
Number of Measles-Rubella vaccines doses		38,800		
Annual Amounts (US\$)		25,000		

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

**11. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**12. Self-procurement:** Not applicable

**13. Co-financing obligations for routine:** Reference code: 1820-SLB-18e-X-C

According to the co-financing policy, Solomon Islands falls within the group Accelerated transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020
Number of vaccine doses	30,600	35,800	45,900
Number of AD syringes	22,900	24,000	
Number of re-constitution syringes	3,400	4,000	
Number of safety boxes	300	325	
Value of vaccine doses (US\$)	18,893	22,117	
Total co-financing payments (US\$) (including freight)	21,000	24,500	31,500
Minimum number of doses to be financed from domestic resources	16,256	13,959	14,789
Minimum amount to be financed from domestic resources (US\$)	10,046	8,627	9,140

**14. Co-financing obligations for campaign:** Not applicable

**15. Vaccine introduction grant (in US\$):** 100,000. Payable up to six months before vaccine introduction.

**16. Operational support for campaigns:** Not applicable

**17. Additional reporting requirements:**

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**18. Financial clarifications:** Not applicable.

**19. Other conditions:** As a condition to Gavi's support for measles and rubella, Country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
December 21, 2017